Numed Pharma

Belkins
Numed Pharma is a nationwide wholesale pharmaceutical distributor with an established record of unshakable account management. Thanks to our unique approach to communications and service, we’ve come to dominate the drug industry as the Prime Drug Source for pharmacies nationally. With our large, growing and ambitious telemarketing sales team, Numed is the right work setting for anyone who's looking for a fast paced career in sales. In the biggest industry in the world, we have found the recipe for success. With an engaging remuneration package of base salary plus commission, being conveniently located next to public transport, and being easily accessible from anywhere in New York City, our working environment is one of the best in the prescription drug business.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

POINT-OF-CARE TOOLS IN PHARMACY TAKE OFF

Managed Healthcare Executive | March 02, 2020

news image

New point-of-care (POC) tools that promote communication between providers and patients are establishing themselves as next generation shared decision-making solutions, especially when it comes to medications and issues of insurance coverage, price, and out-of-pocket costs. “When compared to traditional shared decision-making tools, there’s an increased emphasis not just on improving measures such as medication adherence by involving the patient in his or her own care but also on usi...

Read More

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Prnewswire | August 18, 2020

news image

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More

PHARMACY MARKET

PCI PHARMA SERVICES ANNOUNCES THE CLOSING OF ITS ACQUISITION OF LSNE

PCI Pharma Services | December 15, 2021

news image

PCI Pharma Services a leading global contract development and manufacturing organizatio announced the closing of the previously announced acquisition of Lyophilization Services of New England, Inc. a premier contract development and manufacturing organization headquartered in Bedford, New Hampshire. This acquisition is a key step for PCI, as LSNE will expand PCI’s breadth of services as a global CDMO, building on its expertise in specialty manufacturing, clinical trial suppl...

Read More

BUSINESS INSIGHTS

ZENAS BIOPHARMA ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO OBEXELIMAB FROM XENCOR

Xencor, Zenas BioPharma | November 22, 2021

news image

Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelima...

Read More
news image

POINT-OF-CARE TOOLS IN PHARMACY TAKE OFF

Managed Healthcare Executive | March 02, 2020

New point-of-care (POC) tools that promote communication between providers and patients are establishing themselves as next generation shared decision-making solutions, especially when it comes to medications and issues of insurance coverage, price, and out-of-pocket costs. “When compared to traditional shared decision-making tools, there’s an increased emphasis not just on improving measures such as medication adherence by involving the patient in his or her own care but also on usi...

Read More
news image

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Prnewswire | August 18, 2020

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More
news image

PHARMACY MARKET

PCI PHARMA SERVICES ANNOUNCES THE CLOSING OF ITS ACQUISITION OF LSNE

PCI Pharma Services | December 15, 2021

PCI Pharma Services a leading global contract development and manufacturing organizatio announced the closing of the previously announced acquisition of Lyophilization Services of New England, Inc. a premier contract development and manufacturing organization headquartered in Bedford, New Hampshire. This acquisition is a key step for PCI, as LSNE will expand PCI’s breadth of services as a global CDMO, building on its expertise in specialty manufacturing, clinical trial suppl...

Read More
news image

BUSINESS INSIGHTS

ZENAS BIOPHARMA ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO OBEXELIMAB FROM XENCOR

Xencor, Zenas BioPharma | November 22, 2021

Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelima...

Read More